Technology
Health
Pharmaceutical
Theravance Biopharma
$24.019876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$24.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.07 (-0.29%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell TBPH and other stocks, options, ETFs, and crypto commission-free!
About
Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of small molecule medicines. Read More Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
Employees
363
Headquarters
George Town, George Town
Founded
2013
Market Cap
1.34B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
230.35K
High Today
$24.83
Low Today
$23.57
Open Price
$24.15
Volume
68.28K
52 Week High
$35.48
52 Week Low
$21.04
Collections
Technology
Health
Pharmaceutical
Biopharmaceutical
2014 IPO
North America (Non-US/Canada)
North America
News
Yahoo FinanceMar 13
Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study
Theravance Biopharma, Inc. TBPH has dosed the first patient in a phase IIb/III study on its gut-selective pan-Janus kinase (JAK) inhibitor, TD-1473 in patients with moderately to severely active ulcerative colitis. TD-1473 is currently being developed in collaboration with Janssen, a subsidiary of Johnson & Johnson JNJ, for treating inflammatory intestinal diseases. The phase IIb dose-finding induction portion of the study will assess the effect of eight weeks of treatment with select once-daily doses of T...
Yahoo FinanceFeb 27
Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates
Theravance Biopharma, Inc. TBPH incurred a loss of 92 cents per share in fourth-quarter 2018, narrower than the Zacks Consensus Estimate of a loss of $1.12 and the year-ago loss of $1.64. Total revenues in the quarter under review skyrocketed 248.5% year over year to $15.7 million, mainly on the back of an upfront payment received from Johnson & Johnson JNJ in relation to a joint development agreement for Theravance’s pan-Janus kinase inhibitor, TD-1473. Moreover, the top line surpassed the Zacks Consensus...
The Motley FoolFeb 26
Theravance Biopharma Inc (TBPH) Q4 2018 Earnings Conference Call Transcript
Theravance Biopharma Inc (NASDAQ:TBPH) Q4 2018 Earnings Conference Call , 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Ladies and gentlemen, good afternoon. At this time, I would like to welcome everyone to the Theravance Biopharma Conference Call. During the presentation, all participants will be in a listen-only mode. A question-and-answer session will follow the Company's formal remarks. (Operator Instructions) Today's conference call...
Price Paid on Robinhood
16% Lower
Right Now
52 Week Low
$21.04
Average Price Paid
$28.71
52 Week High
$35.48
Earnings
-$1.64
-$1.35
-$1.05
-$0.76
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 7, After Hours